HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis.

Abstract
We treated, in a preliminary open trial, 31 patients presenting with cognitive impairment, progressive bilateral motor dysfunction, and leukoaraiosis on computed tomography (CT) with a 90-mg daily dose of nimodipine for a period as long as 1 year (minimum: 96 days, maximum: 424 days), to study the safety and possible effects on functional and cognitive conditions throughout this period. Of the 29 patients who had been followed for at least 9 months, most (82%) remained stable or improved as evaluated by the Global Deterioration Scale. A significant improvement was observed in the total Sandoz Clinical Assessment Geriatric scale score (44.66 +/- 7.17 at baseline vs. 36.86 +/- 9.34 at exit, analysis-of-variance time effect, p < 0.0001). These data indicate that nimodipine, chronically administered in patients presenting with cognitive impairment, progressive bilateral motor dysfunction, and leukoaraiosis on CT, is safe and might have beneficial effect, to be confirmed by a randomized trial.
AuthorsL Pantoni, M Carosi, S Amigoni, M Mascalchi, D Inzitari
JournalClinical neuropharmacology (Clin Neuropharmacol) Vol. 19 Issue 6 Pg. 497-506 (Dec 1996) ISSN: 0362-5664 [Print] United States
PMID8937788 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Vasodilator Agents
  • Nimodipine
Topics
  • Adult
  • Aged
  • Cerebrovascular Disorders (drug therapy)
  • Cognition Disorders (drug therapy)
  • Dementia, Vascular (drug therapy)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Nimodipine (adverse effects, therapeutic use)
  • Vasodilator Agents (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: